JP2022530773A5 - - Google Patents
Info
- Publication number
- JP2022530773A5 JP2022530773A5 JP2021563640A JP2021563640A JP2022530773A5 JP 2022530773 A5 JP2022530773 A5 JP 2022530773A5 JP 2021563640 A JP2021563640 A JP 2021563640A JP 2021563640 A JP2021563640 A JP 2021563640A JP 2022530773 A5 JP2022530773 A5 JP 2022530773A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- car
- cells
- car polypeptide
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024205060A JP2025028959A (ja) | 2019-04-30 | 2024-11-26 | 抗原特異的cd19標的化car-t細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840774P | 2019-04-30 | 2019-04-30 | |
| US62/840,774 | 2019-04-30 | ||
| PCT/US2020/030435 WO2020223327A1 (en) | 2019-04-30 | 2020-04-29 | Antigen specific cd19-targeted car-t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024205060A Division JP2025028959A (ja) | 2019-04-30 | 2024-11-26 | 抗原特異的cd19標的化car-t細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530773A JP2022530773A (ja) | 2022-07-01 |
| JP2022530773A5 true JP2022530773A5 (cg-RX-API-DMAC7.html) | 2023-05-09 |
| JP7595583B2 JP7595583B2 (ja) | 2024-12-06 |
Family
ID=73029201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563640A Active JP7595583B2 (ja) | 2019-04-30 | 2020-04-29 | 抗原特異的cd19標的化car-t細胞 |
| JP2024205060A Pending JP2025028959A (ja) | 2019-04-30 | 2024-11-26 | 抗原特異的cd19標的化car-t細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024205060A Pending JP2025028959A (ja) | 2019-04-30 | 2024-11-26 | 抗原特異的cd19標的化car-t細胞 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12617849B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3962955A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7595583B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220005541A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114026128A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020265652A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021021608A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3138276A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL287440A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021013368A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020223327A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| BR112021021608A2 (pt) | 2019-04-30 | 2021-12-21 | Atara Biotherapeutics Inc | Células car-t direcionadas a cd19 específicas para antígeno |
| CA3209218A1 (en) * | 2021-01-27 | 2022-08-04 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Bi-specific car t cells for b cell malignancies |
| US20230303655A1 (en) * | 2021-10-18 | 2023-09-28 | Kite Pharma, Inc. | Signaling domains for chimeric antigen receptors |
| WO2023122337A1 (en) * | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
| CN115725001A (zh) * | 2022-12-08 | 2023-03-03 | 湖南光琇高新生命科技有限公司 | 靶向cd19的嵌合抗原受体、核酸、重组载体及car-t细胞 |
| WO2024173769A2 (en) * | 2023-02-17 | 2024-08-22 | IN8bio, Inc. | Non-signaling chimeric antigen receptor gamma delta t-cells |
| CN116218786B (zh) * | 2023-03-09 | 2024-01-23 | 山东大学齐鲁医院 | 一种多重基因编辑的通用型巨噬细胞及在制备抗肿瘤药物中的应用 |
| CN122138982A (zh) * | 2023-10-26 | 2026-06-02 | 上海先博生物科技有限公司 | 靶向cd19的嵌合抗原受体的治疗用途 |
| CN119285758B (zh) * | 2024-10-31 | 2025-07-01 | 上海百英生物科技股份有限公司 | 一种基于b细胞永生化的单个b细胞抗体开发方法及其应用 |
| CN121673421A (zh) * | 2025-10-24 | 2026-03-17 | 卡瑞济(北京)生命科技有限公司 | 一种靶向EGFRvIII的嵌合抗原受体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3858379A1 (en) | 2013-11-21 | 2021-08-04 | Autolus Limited | Cell |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| MX2018001568A (es) * | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| CN106467906B (zh) | 2015-08-20 | 2019-09-27 | 北京马力喏生物科技有限公司 | 构建体、转基因淋巴细胞及其制备方法和用途 |
| JP7467117B2 (ja) | 2016-10-07 | 2024-04-15 | ノバルティス アーゲー | 癌の治療のためのキメラ抗原受容体 |
| CA3049652A1 (en) * | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| WO2019060174A1 (en) | 2017-09-22 | 2019-03-28 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CHIMERIC ANTIGENIC RECEPTORS WITH ENHANCED NFKB SIGNALING |
| CN111212663A (zh) | 2017-07-07 | 2020-05-29 | H·李·莫菲特癌症中心研究所公司 | 具有突变的cd28共刺激性结构域的嵌合抗原受体 |
| CN108383914A (zh) | 2018-02-23 | 2018-08-10 | 北京美康基免生物科技有限公司 | 一种基于cd19的嵌合抗原受体及其应用 |
| AU2019243315A1 (en) | 2018-03-29 | 2020-09-24 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
| BR112021021608A2 (pt) | 2019-04-30 | 2021-12-21 | Atara Biotherapeutics Inc | Células car-t direcionadas a cd19 específicas para antígeno |
-
2020
- 2020-04-29 BR BR112021021608A patent/BR112021021608A2/pt unknown
- 2020-04-29 CA CA3138276A patent/CA3138276A1/en active Pending
- 2020-04-29 MX MX2021013368A patent/MX2021013368A/es unknown
- 2020-04-29 WO PCT/US2020/030435 patent/WO2020223327A1/en not_active Ceased
- 2020-04-29 JP JP2021563640A patent/JP7595583B2/ja active Active
- 2020-04-29 KR KR1020217038832A patent/KR20220005541A/ko active Pending
- 2020-04-29 CN CN202080044250.9A patent/CN114026128A/zh active Pending
- 2020-04-29 AU AU2020265652A patent/AU2020265652A1/en active Pending
- 2020-04-29 US US17/607,592 patent/US12617849B2/en active Active
- 2020-04-29 EP EP20798656.3A patent/EP3962955A4/en active Pending
-
2021
- 2021-10-20 IL IL287440A patent/IL287440A/en unknown
-
2024
- 2024-11-26 JP JP2024205060A patent/JP2025028959A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| JP2020513839A5 (cg-RX-API-DMAC7.html) | ||
| IL277398B2 (en) | Pd-l1 binding affimers, and uses related thereto | |
| RU2017105160A (ru) | Лечение рака с помощью химерного антигенного рецептора к cd33 | |
| JP2022109975A5 (cg-RX-API-DMAC7.html) | ||
| JP2018527014A5 (cg-RX-API-DMAC7.html) | ||
| RU2017108903A (ru) | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей | |
| US20220389075A1 (en) | Engineered t cell receptors and uses thereof | |
| JP2017522879A5 (cg-RX-API-DMAC7.html) | ||
| JP2019531328A (ja) | セレブロン系のヘテロ二量体化可能なキメラ抗原受容体 | |
| JP2021530233A5 (cg-RX-API-DMAC7.html) | ||
| WO2017079705A1 (en) | Chimeric receptors containing traf-inducing domains and related compositions and methods | |
| CA3080109A1 (en) | Cd38-directed chimeric antigen receptor constructs | |
| JP2024517027A5 (cg-RX-API-DMAC7.html) | ||
| US20230257441A1 (en) | Compositions and methods for treating cancers | |
| JP2024534847A5 (cg-RX-API-DMAC7.html) | ||
| AU2021328478A1 (en) | Compositions and methods for treating egfr positive cancers | |
| JP2022538425A5 (cg-RX-API-DMAC7.html) | ||
| JP2025511409A5 (cg-RX-API-DMAC7.html) | ||
| JP2023518930A5 (cg-RX-API-DMAC7.html) | ||
| WO2021252635A1 (en) | Compositions and methods for treating cancers | |
| JP2025513427A5 (cg-RX-API-DMAC7.html) | ||
| US20240261330A1 (en) | CD19-Directed Chimeric Antigen Receptor Constructs | |
| JP2023518931A5 (cg-RX-API-DMAC7.html) | ||
| EP4712986A1 (en) | Immune cells with paired receptors and uses thereof |